Recombinant adeno-associated virus for delivery of KH902 and uses thereof

Aspects of the present disclosure relate to a recombinant adenovirus (e.g., rAAV2.7 m8-KH902) encoding an anti-vascular endothelial cell growth factor (VEGF) agent in a cell or subject. In some embodiments, the compositions described herein may be used to treat a subject having a disease associated...

Full description

Saved in:
Bibliographic Details
Main Authors PONZO, CARLO, KE ZHIJUN, GAO GUANGPING, P.DAI
Format Patent
LanguageChinese
English
Published 11.11.2022
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Aspects of the present disclosure relate to a recombinant adenovirus (e.g., rAAV2.7 m8-KH902) encoding an anti-vascular endothelial cell growth factor (VEGF) agent in a cell or subject. In some embodiments, the compositions described herein may be used to treat a subject having a disease associated with angiogenesis or aberrant VEGF activity/signaling. 本公开的多个方面涉及在细胞或受试者中编码抗血管内皮细胞生长因子(VEGF)剂的重组腺病毒(例如，rAAV2.7m8-KH902)。在一些实施方案中，本文所述的组合物可用于治疗患有与血管生成或异常的VEGF活性/信号传导相关的疾病的受试者。
Bibliography:Application Number: CN20208094587